Latest Oncology News

Page 2 of 18
Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.
Ada Torres
Ada Torres
5 Dec 2025
OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.
Ada Torres
Ada Torres
3 Dec 2025
Optiscan Imaging Ltd has initiated Australia’s first intra-operative head and neck cancer imaging study using its advanced InVue® and InForm™ devices, aiming to enhance surgical precision and support FDA regulatory submissions.
Ada Torres
Ada Torres
3 Dec 2025
Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.
Ada Torres
Ada Torres
2 Dec 2025
Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.
Ada Torres
Ada Torres
27 Nov 2025
Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.
Victor Sage
Victor Sage
27 Nov 2025
Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.
Ada Torres
Ada Torres
27 Nov 2025
Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.
Ada Torres
Ada Torres
26 Nov 2025
Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.
Ada Torres
Ada Torres
25 Nov 2025
Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.
Ada Torres
Ada Torres
24 Nov 2025
Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.
Ada Torres
Ada Torres
18 Nov 2025
Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.
Ada Torres
Ada Torres
17 Nov 2025